SEARCH:   Advanced

Blood, 15 July 2005, Vol. 106, No. 2, pp. 464-469. Prepublished online as a Blood First Edition Paper on March 29, 2005; DOI 10.1182/blood-2005-02-0698. This Article Full Text (PDF) All Versions of this Article: 2005-02-0698v1 106/2/464    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hui, C.-k. Articles by Lau, G. K Search for Related Content PubMed PubMed Citation Articles by Hui, C.-k. Articles by Lau, G. K Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 18, 2005 Accepted March 18, 2005 A long-term follow-up study on hepatitis B surface antigen positive patients undergoing allogeneic hematopoietic stem cell transplantation Chee-kin Hui, Albert Lie, Wing-yan Au, Yu-hung Leung, Shing-yan Ma, Winnie W Cheung, Hai-ying Zhang, Chor-sum Chim, Yok-lam Kwong, Raymond Liang, and George K Lau* Division of Gastroenterology and Hepatology, The University of Hong Kong, Hong Kong SAR, Hong Kong, China; Centre For The Study of Liver Diseases, The University of Hong Kong, Hong Kong, China Division of Hematology, Department of Medicine, The University of Hong Kong, Hong Kong SAR, Hong Kong, China * Corresponding author; email: gkklau{at}netvigator.com. The long-term hepatic complications after allogeneic hematopoietic stem cell transplantation (HSCT) in hepatitis B virus (HBV) endemic area are unknown. We examined the serological and liver-related outcome of 803 consecutive allogeneic HSCT recipients with a median follow-up period of 83 months (range: 0.5-155). Late HBV-related hepatitis occurred in 2 of the 721 hepatitis B surface antigen (HBsAg) negative recipients compared with 16 of the 82 HBsAg positive recipients after HSCT (0.3% vs. 19.5%, p< 0.001 by log-rank). Liver cirrhosis developed in 8 of the 82 HBsAg positive recipients compared with none of the 721 HBsAg negative recipients (9.8% vs. 0%, p< 0.001 by log-rank). Twenty of the 31 (64.5%) HBsAg positive recipients of hematopoietic stem cell from donors with natural immunity to HBV had sustained serological clearance of HBsAg after HSCT. Eight of the 62 recipients without sustained HBsAg clearance compared with none of the 20 recipients with sustained HBsAg clearance developed liver cirrhosis (12.9% vs. 0%, p=0.02 by log-rank). Our study showed that long-term hepatic complications occur in a significant proportion of HBsAg positive patients after HSCT and the incidence of liver cirrhosis is reduced in those with sustained serological clearance of HBsAg after HSCT. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020